Literature DB >> 27601468

Interleukin 2 Activates Brain Microvascular Endothelial Cells Resulting in Destabilization of Adherens Junctions.

Lukasz S Wylezinski1, Jacek Hawiger2,3,4.   

Abstract

The pleiotropic cytokine interleukin 2 (IL2) disrupts the blood-brain barrier and alters brain microcirculation, underlying vascular leak syndrome that complicates cancer immunotherapy with IL2. The microvascular effects of IL2 also play a role in the development of multiple sclerosis and other chronic neurological disorders. The mechanism of IL2-induced disruption of brain microcirculation has not been determined previously. We found that both human and murine brain microvascular endothelial cells express constituents of the IL2 receptor complex. Then we established that signaling through this receptor complex leads to activation of the transcription factor, nuclear factor κB, resulting in expression of proinflammatory interleukin 6 and monocyte chemoattractant protein 1. We also discovered that IL2 induces disruption of adherens junctions, concomitant with cytoskeletal reorganization, ultimately leading to increased endothelial cell permeability. IL2-induced phosphorylation of vascular endothelial cadherin (VE-cadherin), a constituent of adherens junctions, leads to dissociation of its stabilizing adaptor partners, p120-catenin and β-catenin. Increased phosphorylation of VE-cadherin was also accompanied by a reduction of Src homology 2 domain-containing protein-tyrosine phosphatase 2, known to maintain vascular barrier function. These results unravel the mechanism of deleterious effects induced by IL2 on brain microvascular endothelial cells and may inform the development of new measures to improve IL2 cancer immunotherapy, as well as treatments for autoimmune diseases affecting the central nervous system.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  brain; cancer therapy; endothelial cell; inflammation; interleukin 2; permeability

Mesh:

Substances:

Year:  2016        PMID: 27601468      PMCID: PMC5087713          DOI: 10.1074/jbc.M116.729038

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Review: leucocyte-endothelial cell crosstalk at the blood-brain barrier: a prerequisite for successful immune cell entry to the brain.

Authors:  J Greenwood; S J Heasman; J I Alvarez; A Prat; R Lyck; B Engelhardt
Journal:  Neuropathol Appl Neurobiol       Date:  2011-02       Impact factor: 8.090

3.  SHP2 association with VE-cadherin complexes in human endothelial cells is regulated by thrombin.

Authors:  J A Ukropec; M K Hollinger; S M Salva; M J Woolkalis
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

4.  The effect of intravenous interleukin-2 on brain water content.

Authors:  S C Saris; N J Patronas; S A Rosenberg; J T Alexander; J Frank; D J Schwartzentruber; J T Rubin; D Barba; E H Oldfield
Journal:  J Neurosurg       Date:  1989-08       Impact factor: 5.115

5.  Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.

Authors:  Carsten Krieg; Sven Létourneau; Giuseppe Pantaleo; Onur Boyman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

6.  Leukocyte extravasation and vascular permeability are each controlled in vivo by different tyrosine residues of VE-cadherin.

Authors:  Florian Wessel; Mark Winderlich; Maren Holm; Maike Frye; Ronmy Rivera-Galdos; Matthias Vockel; Ruth Linnepe; Ute Ipe; Anika Stadtmann; Alexander Zarbock; Astrid F Nottebaum; Dietmar Vestweber
Journal:  Nat Immunol       Date:  2014-02-09       Impact factor: 25.606

7.  Down-regulation of platelet endothelial cell adhesion molecule-1 results in thrombospondin-1 expression and concerted regulation of endothelial cell phenotype.

Authors:  N Sheibani; W A Frazier
Journal:  Mol Biol Cell       Date:  1998-04       Impact factor: 4.138

8.  Neural Wiskott-Aldrich syndrome protein (N-WASP)-mediated p120-catenin interaction with Arp2-Actin complex stabilizes endothelial adherens junctions.

Authors:  Charu Rajput; Vidisha Kini; Monica Smith; Pascal Yazbeck; Alejandra Chavez; Tracy Schmidt; Wei Zhang; Nebojsa Knezevic; Yulia Komarova; Dolly Mehta
Journal:  J Biol Chem       Date:  2012-12-04       Impact factor: 5.157

9.  Proteolytic processing of NF-kappa B/I kappa B in human monocytes. ATP-dependent induction by pro-inflammatory mediators.

Authors:  R Donald; D W Ballard; J Hawiger
Journal:  J Biol Chem       Date:  1995-01-06       Impact factor: 5.157

10.  Fibroblast growth factor signaling potentiates VE-cadherin stability at adherens junctions by regulating SHP2.

Authors:  Kunihiko Hatanaka; Anthony A Lanahan; Masahiro Murakami; Michael Simons
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

View more
  15 in total

1.  Virus entry and replication in the brain precedes blood-brain barrier disruption during intranasal alphavirus infection.

Authors:  Matthew D Cain; Hamid Salimi; Yongfeng Gong; Lihua Yang; Samantha L Hamilton; James R Heffernan; Jianghui Hou; Mark J Miller; Robyn S Klein
Journal:  J Neuroimmunol       Date:  2017-05-01       Impact factor: 3.478

2.  Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain.

Authors:  Lei Zhao; Zhongqi Li; Joaquim S L Vong; Xinyi Chen; Hei-Ming Lai; Leo Y C Yan; Junzhe Huang; Samuel K H Sy; Xiaoyu Tian; Yu Huang; Ho Yin Edwin Chan; Hon-Cheong So; Wai-Lung Ng; Yamei Tang; Wei-Jye Lin; Vincent C T Mok; Ho Ko
Journal:  Nat Commun       Date:  2020-09-04       Impact factor: 14.919

3.  Anesthesia and Surgery Impair Blood-Brain Barrier and Cognitive Function in Mice.

Authors:  Siming Yang; Changping Gu; Emiri T Mandeville; Yuanlin Dong; Elga Esposito; Yiying Zhang; Guang Yang; Yuan Shen; Xiaobing Fu; Eng H Lo; Zhongcong Xie
Journal:  Front Immunol       Date:  2017-08-09       Impact factor: 7.561

Review 4.  Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.

Authors:  Lorenzo Mortara; Enrica Balza; Antonino Bruno; Alessandro Poggi; Paola Orecchia; Barbara Carnemolla
Journal:  Front Immunol       Date:  2018-12-18       Impact factor: 7.561

Review 5.  Maternal Antibody and ASD: Clinical Data and Animal Models.

Authors:  Adriana Gata-Garcia; Betty Diamond
Journal:  Front Immunol       Date:  2019-05-28       Impact factor: 7.561

6.  Four Cysteine Residues Contribute to Homodimerization of Chicken Interleukin-2.

Authors:  Chen Deng; Hailiang Tan; Hongda Zhou; Mengyun Wang; Yan Lü; Jiacui Xu; Huanmin Zhang; Limei Han; Yongxing Ai
Journal:  Int J Mol Sci       Date:  2019-11-15       Impact factor: 5.923

7.  L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model.

Authors:  Paola Orecchia; Enrica Balza; Gabriella Pietra; Romana Conte; Nicolò Bizzarri; Simone Ferrero; Maria Cristina Mingari; Barbara Carnemolla
Journal:  Cancers (Basel)       Date:  2019-08-23       Impact factor: 6.639

Review 8.  Decoding inflammation, its causes, genomic responses, and emerging countermeasures.

Authors:  Jacek Hawiger; Jozef Zienkiewicz
Journal:  Scand J Immunol       Date:  2019-08-28       Impact factor: 3.487

9.  The Amino Acid-mTORC1 Pathway Mediates APEC TW-XM-Induced Inflammation in bEnd.3 Cells.

Authors:  Dong Zhang; Shu Xu; Yiting Wang; Peng Bin; Guoqiang Zhu
Journal:  Int J Mol Sci       Date:  2021-08-26       Impact factor: 5.923

10.  Cromolyn platform suppresses fibrosis and inflammation, promotes microglial phagocytosis and neurite outgrowth.

Authors:  Yi-Jun Wang; Matthew A Downey; Sungwoon Choi; Timothy M Shoup; David R Elmaleh
Journal:  Sci Rep       Date:  2021-11-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.